Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Talbot

Showing results (541-550 of 576) with videos related to

Pageof 58
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|September 20, 2011
Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrestGeorge J Arnaoutakis, Timothy J George, Kevin K Wang, et al.
Scientific Reports|March 16, 2019
Contemporary limnology of the rapidly changing glacierized watershed of the world's largest High Arctic lakeK A St Pierre, V L St Louis, I Lehnherr, et al.
British Journal of Cancer|October 26, 2019
Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015Tracey S E Genus, Catherine Bouvier, Kwok F Wong, et al.
ACS Medicinal Chemistry Letters|August 25, 2017
Design and Optimization of Benzopiperazines as Potent Inhibitors of BET BromodomainsDavid S Millan, Katherine J Kayser-Bricker, Matthew W Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancerN C Levitt, F A Eskens, K J O'Byrne, et al.
Neuroreport|July 8, 1996
Structure and alternative splicing of the presenilin-2 geneG Prihar, R A Fuldner, J Perez-Tur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Cell Reports|February 2, 2022
SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated stateJessica Y Hsu, Etienne P Danis, Stephanie Nance, et al.
Human Molecular Genetics|July 23, 2021
Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeuticsSergey S Akimov, Mali Jiang, Amanda J Kedaigle, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Pageof 58

Showing results (541-550 of 576) with videos related to

Sort By:
Pageof 58
The Journal of Thoracic and Cardiovascular Surgery|September 20, 2011
Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrestGeorge J Arnaoutakis, Timothy J George, Kevin K Wang, et al.
Scientific Reports|March 16, 2019
Contemporary limnology of the rapidly changing glacierized watershed of the world's largest High Arctic lakeK A St Pierre, V L St Louis, I Lehnherr, et al.
British Journal of Cancer|October 26, 2019
Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015Tracey S E Genus, Catherine Bouvier, Kwok F Wong, et al.
ACS Medicinal Chemistry Letters|August 25, 2017
Design and Optimization of Benzopiperazines as Potent Inhibitors of BET BromodomainsDavid S Millan, Katherine J Kayser-Bricker, Matthew W Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancerN C Levitt, F A Eskens, K J O'Byrne, et al.
Neuroreport|July 8, 1996
Structure and alternative splicing of the presenilin-2 geneG Prihar, R A Fuldner, J Perez-Tur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Cell Reports|February 2, 2022
SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated stateJessica Y Hsu, Etienne P Danis, Stephanie Nance, et al.
Human Molecular Genetics|July 23, 2021
Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeuticsSergey S Akimov, Mali Jiang, Amanda J Kedaigle, et al.
Cancer|November 2, 2018
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC)Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, et al.
Pageof 58